A Phase III study of pemborlizumab (MK-3475) vs chemotherapy in microstatellite instablility - High (MSI-H) or mismatch repair deficienct (dMMR) stage IV colorectal carcinoma (Keynote - 177)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
May 1, 2016
End Date
July 5, 2018
Administered By
Duke Cancer Institute
Awarded By
Merck Sharp & Dohme
Start Date
May 1, 2016
End Date
July 5, 2018